The main nonhematologic toxicities were grade 2/3 nausea/vomiting (7 cycles; 5%), grade 2/3 neurotoxicity (10 cycles; 7%), grade 2/3 asthenia (8 cycles; 5.5%) and grade 2/3 diarrhea (6 cycles; 4%). There was no treatment-related death. [ncbi.nlm.nih.gov]

Interrupt, adjust dose, and/or treat symptoms if toxicity occurs (eg, hyperbilirubinemia, diarrhea, nausea, vomiting, hand-and-foot syndrome, stomatitis) (see full labeling); do not increase dose afterwards. [infectiousdiseaseadvisor.com]

Instruct patient to immediately report nausea, vomiting, diarrhea, mouth ulcers, swollen joints, temperature above 100.5 F (38 C), and other signs or symptoms of infection. • Tell patient to expect dosage adjustments during therapy. • Urge patient to [medical-dictionary.thefreedictionary.com]

disease, infection, coagulopathy • children younger than age 18. [medical-dictionary.thefreedictionary.com]

Diseases Rectal Diseases Bevacizumab Capecitabine Angiogenesis Inhibitors Angiogenesis Modulating Agents Growth Substances Physiological Effects of Drugs Growth Inhibitors Antineoplastic Agents Antimetabolites, Antineoplastic Antimetabolites Molecular [clinicaltrials.gov]

Diseases / Intestinal Neoplasms / Neoplasms, Colorectal / Rectal Carcinoma / Rectal Neoplasms 1 2RecruitingTreatment Colorectal Cancers 1 2RecruitingTreatment Colorectal Large Cell Neuroendocrine Carcinoma / Esophageal Large Cell Neuroendocrine Carcinoma [drugbank.ca]

It causes symptoms like a new breast lump or mass, swelling of all or part of a breast, skin irritation or dimpling, breast or nipple pain, nipple retraction, redness, scaliness, or thickening of the nipple or breast skin, and nipple discharge other than [breastcancer-news.com]

It causes symptoms like a new breast lump or mass, swelling of all or part of a breast, skin irritation or dimpling, breast or nipple pain, nipple retraction, redness, scaliness, or thickening of the nipple or breast skin, and nipple discharge other than [breastcancer-news.com]

[…] anti-ErbB1 and/or ErbB2 inhibitor therapy for breast cancer; neoadjuvant or adjuvant treatment with trastuzumab will be allowed provided the last dose was 6 months prior to enrollment in study Symptomatic or untreated brain metastases or carcinomatous meningitis [clinicaltrials.gov]

In addition, between 1 and 10 percent of the patients experience constipation, headaches, and dizziness, eye problems, hair loss or hair thinning, abdominal pain, loss of appetite, high levels of bilirubin in the blood, amenorrhea, and loss of fertility [breastcancer-news.com]